한글목차

암 유전자 치료 세계 시장 규모는 2030년까지 88억 달러에 달할 것으로 예상됩니다

2023년 23억 달러로 추정되는 암 유전자 치료 세계 시장은 2023-2030년의 분석 기간 동안 연평균 21.1% 성장하여 2030년에는 88억 달러에 달할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 암 바이러스 치료는 CAGR 21.9%를 기록하여 분석 기간 종료 시점에 43억 달러에 도달할 것으로 예상됩니다. 유전자 도입 치료 분야의 성장률은 분석 기간 동안 CAGR 15.7%로 추정됩니다.

미국 시장은 6억 1,540만 달러로 추정, 중국은 CAGR 20.0%로 성장 전망

미국의 암 유전자 치료 시장은 2023년 6억 1,540만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 13억 달러 규모에 도달할 것으로 예상되며, 2023-2030년의 분석 기간 동안 20.0%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 19.0%와 17.6%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 약 14.0%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

세계 암 유전자치료제 시장 - 주요 동향 및 촉진요인 정리

암 유전자 치료가 암 치료에 혁명을 가져올 이유는 무엇인가?

암 유전자 치료는 단순히 증상을 치료하는 것이 아니라 암의 유전적 근본 원인을 표적으로 삼아 혁신적인 솔루션을 제공하는 암 퇴치의 획기적인 접근법입니다. 화학요법이나 방사선과 같이 건강한 세포와 암세포를 모두 공격하는 기존 치료법과는 달리, 유전자 치료는 암의 발생과 확산을 유발하는 유전자를 변경하거나 복구하는 것을 목표로 합니다. CRISPR 기술을 이용한 유전자 편집이나 바이러스 벡터를 이용한 치료용 유전자 도입과 같은 기술을 통해 의사는 돌연변이된 유전자를 대체하거나 암과 싸우는 데 도움이 되는 새로운 유전자를 도입하거나 암세포를 면역체계가 더 쉽게 인식할 수 있도록 하는 등 보다 정확하고 잠재적으로 덜 해로운 대안을 제공합니다. 암세포를 면역체계가 인식하기 쉽게 만들 수 있습니다. 암 유전자 치료의 영향은 치료뿐만 아니라 장기적인 관해와 경우에 따라서는 완치를 가져올 수도 있습니다. 암의 유전적 기반을 조작할 수 있는 능력은 치료 접근 방식의 기념비적인 전환을 의미하며, 암 치료를 획일적인 모델에서 보다 개인화되고 효과적인 전략으로 전환할 수 있습니다.

기술의 발전은 암 유전자 치료를 어떻게 형성하고 있는가?

기술 혁신은 암 유전자 치료의 급속한 발전의 원동력입니다. 최근 가장 중요한 동향은 CRISPR-Cas9의 부상으로, 과학자들이 암세포 내 유전자를 정확하게 수정할 수 있는 유전자 편집 기술인 CRISPR-Cas9의 등장입니다. 이 도구는 이 분야에 혁명을 일으켜 연구자들이 돌연변이를 수정하거나 암 진행에 기여하는 유전자를 제거할 수 있게 되었습니다. 치료용 유전자를 암세포에 직접 전달하는 바이러스 벡터도 벡터 공학의 혁신으로 인해 더욱 효율적이고 안전해졌습니다. 이러한 벡터는 환자에게 해를 끼치지 않고 유전 물질을 세포 내로 운반할 수 있는 방법을 제공하기 때문에 유전자 치료에 매우 중요합니다. 또한, 차세대 염기서열 분석(NGS)은 개별 암을 유발하는 유전자 변이에 대한 더 깊은 통찰력을 제공함으로써 암 유전자 치료를 발전시키고 있습니다. 이 기술은 환자의 암에 특화된 유전자 프로파일에 기반한 고도의 맞춤 치료를 가능하게 합니다. 인공지능과 머신러닝 또한 대규모 데이터 세트를 분석하고 유전자 치료 개입의 결과를 예측하여 효과적인 치료법을 쉽게 설계할 수 있도록 하는 데 중요한 역할을 하고 있습니다. 이러한 기술 발전은 유전자 치료의 접근성을 높였을 뿐만 아니라, 안전성과 유효성을 향상시켜 종양학 분야의 성장을 가속하고 있습니다.

암 유전자 치료의 새로운 트렌드와 과제는?

현재 암 유전자 치료 시장을 형성하고 있는 몇 가지 주요 트렌드가 있으며, 각 트렌드는 이 혁신적인 치료법을 확장하고 개선하는 데 기여하고 있습니다. 가장 눈에 띄는 트렌드 중 하나는 개인 맞춤형 의료에 대한 관심이 높아지고 있다는 점입니다. 암 유전자 치료가 환자 개개인의 유전적 체질에 따라 맞춤화됨에 따라 업계는 더 나은 치료 결과를 제공하는 고도로 맞춤화된 치료로 전환하고 있습니다. 또 다른 추세는 면역치료와 유전자 치료의 병용이 증가하고 있다는 점입니다. 암세포를 인식하고 파괴하는 면역체계의 능력을 강화함으로써, 이러한 치료법은 다양한 암종 치료에 더욱 효과적이고 다재다능한 치료법이 되고 있습니다. 그러나 이러한 발전에도 불구하고, 암 유전자 치료는 몇 가지 문제에 직면해 있습니다. 가장 큰 문제 중 하나는 많은 환자와 의료 시스템에서 감당하기 어려운 치료 비용입니다. 또한, 규제 장벽과 긴 임상시험 일정 등 유전자 치료제 개발의 복잡성 또한 광범위한 시장 도입에 걸림돌로 작용하고 있습니다. 또한, 표적 외 효과와 예상치 못한 면역 반응의 위험이 항상 존재하기 때문에 유전자 치료의 안전성 확보는 여전히 우려되는 부분입니다. 이러한 장애물에도 불구하고, 기술 혁신의 빠른 속도와 암 유전학에 대한 이해도가 높아지면서 암 유전자 치료제의 개발이 계속 추진되고 있습니다.

암 유전자 치료제 시장의 주요 성장 촉진요인은 무엇인가?

암 유전자 치료 시장의 성장은 유전자 편집 기술의 발전, 개인 맞춤형 의료에 대한 관심 증가, 전 세계 암 발병률 증가 등 여러 요인에 의해 주도되고 있습니다. 가장 큰 원동력 중 하나는 CRISPR-Cas9 및 기타 유전자 편집 기술과 같은 도구의 개발로 암 유전자 치료의 정확성과 효능을 크게 향상시키고 있습니다. 더 많은 환자와 의료진이 환자의 암을 유발하는 개별 유전자 변이에 맞는 치료를 원하는 개인 맞춤형 의료의 발전도 큰 성장 동력이 되고 있습니다. 이러한 맞춤형 표적치료에 대한 수요로 인해 유전자 치료 연구개발에 대한 투자가 증가하고 있습니다. 또한, 전 세계 암 유병률 증가, 특히 고령화 사회에서의 암 증가는 장기적인 해결책 또는 완치를 위한 혁신적인 치료법에 대한 수요 증가에 기여하고 있습니다. 유전자 치료를 통해 면역세포를 변화시켜 암과 싸울 수 있도록 하는 면역치료의 발전은 치료의 가능성을 더욱 넓혀주고 있습니다. 특정 유전자 치료제에 대한 규제 당국의 승인과 획기적인 지정은 시장 진입을 가속화하고 더 빠르게 도입할 수 있도록 돕고 있습니다. 그 결과, 기술 혁신, 개인 맞춤형 접근법, 암 환자 증가와 함께 암 유전자 치료제 시장은 강력한 성장을 거듭하고 있습니다.

조사 대상 기업 예시(총 42건)

• Adaptimmune Therapeutics plc
• Advantagene, Inc.
• Altor Bioscience(NANT Company)
• Anchiano Therapeutics, Inc.
• bluebird bio, Inc.
• Genelux Corporation
• GlaxoSmithKline PLC
• Merck & Co.
• OncoGenex Pharmaceuticals, Inc.
• Shanghai Sunway Biotech Co.
• Shenzhen SiBiono GeneTech Co.
• ZIOPHARM Oncology, Inc.

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 기타 지역

제4장 경쟁

영문목차

Global Cancer Gene Therapy Market to Reach US$8.8 Billion by 2030

The global market for Cancer Gene Therapy estimated at US$2.3 Billion in the year 2023, is expected to reach US$8.8 Billion by 2030, growing at a CAGR of 21.1% over the analysis period 2023-2030. Oncolytic Virotherapy, one of the segments analyzed in the report, is expected to record a 21.9% CAGR and reach US$4.3 Billion by the end of the analysis period. Growth in the Gene Transfer Therapy segment is estimated at 15.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$615.4 Million While China is Forecast to Grow at 20.0% CAGR

The Cancer Gene Therapy market in the U.S. is estimated at US$615.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 20.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.0% and 17.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.0% CAGR.

Global Cancer Gene Therapy Market - Key Trends and Drivers Summarized

Why Is Cancer Gene Therapy Revolutionizing Cancer Treatment?

Cancer gene therapy represents a groundbreaking approach in the fight against cancer, offering innovative solutions by targeting the genetic root causes of cancer rather than just treating the symptoms. Unlike traditional treatments like chemotherapy and radiation, which attack both healthy and cancerous cells, gene therapy aims to alter or repair the genes that cause cancer to develop and spread. This method provides a more precise and potentially less harmful alternative. Techniques such as gene editing, using CRISPR technology, or delivering therapeutic genes via viral vectors, allow doctors to replace mutated genes, introduce new genes that help fight cancer, or make cancer cells more recognizable to the immune system. The impact of cancer gene therapy extends beyond treatment, as it offers long-term remission and, in some cases, even a cure. The ability to manipulate the genetic foundation of cancer represents a monumental shift in how we approach treatment, transforming cancer care from a one-size-fits-all model to a more personalized and effective strategy.

How Are Technological Advances Shaping Cancer Gene Therapy?

Technological innovation is the driving force behind the rapid advancements in cancer gene therapy. The most significant development in recent years is the rise of CRISPR-Cas9, a gene-editing technology that allows scientists to precisely modify genes within cancer cells. This tool has revolutionized the field, enabling researchers to either correct mutations or knock out genes that contribute to cancer progression. Viral vectors, which deliver therapeutic genes directly into cancer cells, are also becoming more efficient and safer, thanks to innovations in vector engineering. These vectors are crucial in gene therapy as they provide a way to transport genetic material into cells without causing harm to the patient. Additionally, next-generation sequencing (NGS) is advancing cancer gene therapy by offering deeper insights into the genetic mutations driving individual cancers. This technology allows for highly personalized treatments based on the specific genetic profile of a patient’s cancer. Artificial intelligence and machine learning are also playing pivotal roles by analyzing large datasets and predicting the outcomes of gene therapy interventions, making it easier to design effective treatments. These technological advances have not only made gene therapy more accessible but have also improved its safety and efficacy, driving its growth in the oncology field.

What Are the Emerging Trends and Challenges in Cancer Gene Therapy?

Several key trends are currently shaping the cancer gene therapy market, each contributing to the expansion and refinement of this innovative treatment modality. One of the most prominent trends is the growing focus on personalized medicine. As cancer gene therapy becomes more tailored to individual patients based on their genetic makeup, the industry is seeing a shift towards highly customized treatments that offer better outcomes. Another trend is the increasing use of immunotherapy in combination with gene therapy. By enhancing the immune system's ability to recognize and destroy cancer cells, these therapies are becoming more effective and versatile in treating various cancer types. However, despite these advancements, cancer gene therapy faces several challenges. One significant issue is the high cost of treatment, which can be prohibitive for many patients and healthcare systems. The complexity of developing gene therapies, including regulatory hurdles and long timelines for clinical trials, also poses a challenge to broader market adoption. Additionally, ensuring the safety of gene therapies remains a concern, as there is always a risk of off-target effects or unwanted immune responses. Despite these obstacles, the rapid pace of innovation and growing understanding of cancer genetics continue to drive the development of cancer gene therapies.

What Are the Key Growth Drivers in the Cancer Gene Therapy Market?

The growth in the cancer gene therapy market is driven by several factors, including advances in gene editing technologies, the increasing focus on personalized medicine, and the rising incidence of cancer globally. One of the most significant drivers is the development of tools like CRISPR-Cas9 and other gene-editing technologies, which have greatly enhanced the precision and effectiveness of cancer gene therapy. The push towards personalized medicine is also a major growth factor, as more patients and healthcare providers seek treatments that are tailored to the individual genetic mutations driving a patient’s cancer. This demand for personalized, targeted treatments has led to increased investment in the research and development of gene therapies. Additionally, the rising prevalence of cancer worldwide, particularly in aging populations, is contributing to the growing need for innovative therapies that can offer long-term solutions or even cures. Immunotherapy advancements, where gene therapy is used to modify immune cells to better fight cancer, are further expanding the therapeutic landscape. Regulatory approvals and breakthrough designations for certain gene therapies are accelerating their entry into the market, allowing for faster adoption. As a result, the combination of technological innovation, personalized approaches, and increasing cancer cases continues to fuel the robust growth of the cancer gene therapy market.

Select Competitors (Total 42 Featured) -

• Adaptimmune Therapeutics plc
• Advantagene, Inc.
• Altor Bioscience (a NANT Company)
• Anchiano Therapeutics, Inc.
• bluebird bio, Inc.
• Genelux Corporation
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• OncoGenex Pharmaceuticals, Inc.
• Shanghai Sunway Biotech Co., Ltd.
• Shenzhen SiBiono GeneTech Co., Ltd.
• ZIOPHARM Oncology, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Cancer Gene Therapy - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Cancer Globally Spurs Growth in Demand for Cancer Gene Therapy
  • Advances in Genomic Research Throw the Spotlight on Precision Cancer Gene Therapies
  • Focus on Personalized Medicine Expands Addressable Market Opportunity for Gene-Based Cancer Treatments
  • Innovations in CRISPR and Gene Editing Propel the Development of Advanced Cancer Gene Therapies
  • Growing Investment in Gene Therapy Research Strengthens the Business Case for Novel Cancer Treatments
  • Shift Towards Targeted Therapy Accelerates Demand for Gene-Based Cancer Solutions
  • Expansion of Immunotherapy Techniques Sustains Growth in the Cancer Gene Therapy Market
  • Rising Interest in Oncolytic Virus Therapy Generates New Opportunities for Cancer Gene Therapy
  • Increasing Use of Next-Generation Sequencing Drives the Development of Precision Cancer Gene Therapies
  • Growing Focus on Rare and Aggressive Cancers Expands Market Potential for Gene Therapy Solutions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cancer Gene Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cancer Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Cancer Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Cancer Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Oncolytic Virotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Oncolytic Virotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Oncolytic Virotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Gene Transfer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Gene Transfer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Gene Transfer Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Gene-Induced Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Gene-Induced Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Gene-Induced Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 14: USA Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 15: USA Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: USA 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 17: Canada Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 18: Canada Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: Canada 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
• JAPAN
  • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 20: Japan Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Japan Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: Japan 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
• CHINA
  • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 23: China Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 24: China Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: China 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
• EUROPE
  • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Cancer Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Cancer Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for Cancer Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: Europe 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
• FRANCE
  • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 32: France Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: France Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: France 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
• GERMANY
  • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 35: Germany Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Germany Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Germany 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 38: Italy Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Italy Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: Italy 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 41: UK Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: UK Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: UK 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Rest of Europe Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: Rest of Europe 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Cancer Gene Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Asia-Pacific Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Asia-Pacific 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Rest of World Historic Review for Cancer Gene Therapy by Segment - Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Rest of World 16-Year Perspective for Cancer Gene Therapy by Segment - Percentage Breakdown of Value Sales for Oncolytic Virotherapy, Gene Transfer Therapy and Gene-Induced Immunotherapy for the Years 2014, 2024 & 2030

IV. COMPETITION